MRD-guided treatment for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
The VISION/HOVON 141 phase II study aims to evaluate options for MRD-guided targeted therapy for patients with R/R CLL. The patients included received a venetoclax+ibrutinib combination treatment in 15 cycles, and those who reached undetectable MRD were randomized 1:2 between maintenance ibrutinib or observation (no therapy). In this MEDtalk Dr. Arnon P. Kater shares that terminating therapy for patients who achieve uMRD shows promising outcomes. The trial is still ongoing.
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.